Status:
COMPLETED
Study of Botulinum Toxin and Recovery of Hand Function After Stroke
Lead Sponsor:
NYU Langone Health
Collaborating Sponsors:
Allergan
Conditions:
Stroke With Hemiparesis
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine whether injections of botulinum toxin (commonly known as BOTOX®) into the affected hand of Stroke patients, while targeting the muscles controlling the hand, ...
Detailed Description
Hemiparesis is the most common motor impairment after stroke that frequently leads to persistent deficits in hand function. This study investigates whether the application of botulinum toxin to a set ...
Eligibility Criteria
Inclusion
- Ability to follow study instructions and likely to complete all required visits
- Ability to comply with the therapy protocol as assessed by the investigator
- 3 months post first-time unilateral stroke with right or left hemiparesis and complaints of unilateral hand dysfunction
- Must have ability to grasp and lift the test object
- Subjects must have upper extremity motor impairment
Exclusion
- Known allergy or sensitivity to botulinum toxin type A (BOTOX).
- Females with a positive pregnancy test, or who are breast-feeding, planning a pregnancy during the study, who think that they may be pregnant at the start of the study or females of childbearing potential who are unable or unwilling to use a reliable form of contraception during the study.
- Concurrent participation in another investigational drug or device study or participation in another Botulinum toxin study in the 6 months prior to study.
- Treatment with botulinum toxin of any serotype in the 3 months prior to study enrollment
- Any medical condition that may put the subject at increased risk with exposure to BOTOX including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amytrophic lateral sclerosis, or any other disorder that might interfere with neuromuscular function.
- Evidence of alcohol, drug abuse or other relevant neuropsychiatric condition.
- Infection or skin disorder at an anticipated injection site.
- Any condition or situation that, in the investigator's opinion, may put the subject at significant risk, confound the study results, or interfere significantly with the subject's participation in the study.
- History of surgery or other significant injury to either upper extremity causing mechanical limitations that preclude task performance.
- Previous neurological illness such as head trauma, prior stroke, epilepsy, or demyelinating disease.
- Complicating medical problems such as uncontrolled hypertension, diabetes with signs of polyneuropathy, severe renal, cardiac or pulmonary disease, or evidence of other concurrent neurologic or orthopedic conditions precluding the subject from complying with the study protocol.
- Current treatment with intrathecal baclofen.
Key Trial Info
Start Date :
April 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2015
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT01422161
Start Date
April 1 2010
End Date
October 1 2015
Last Update
June 20 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
New York University School of Medicine
New York, New York, United States, 10016